ArticleBMC rheumatology2026
Short-course prednisone and methotrexate in a cohort of patients with polymyalgia rheumatica: a potential therapeutic approach.
Article in BMC rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe optimal treatment of polymyalgia rheumatica (PMR) is far from being fully elucidated. Only a few trials explored the role of conventional DMARDs: none of them adequately ruled out subclinical giant cell arteritis (GCA). The aim of this study was to assess whether the precocious administration of methotrexate (MTX) and a short course of glucocorticoids (GCs) could be safe and effective in recently diagnosed PMR.
methodsPatients with a recent diagnosis of PMR were prospectively enrolled, upon exclusion of GCA, and treated with MTX and gradually tapered prednisone (PDN). As a control group, a historical cohort treated with GC-monotherapy was included. The primary endpoint was PDN-free remission at 24 weeks. Secondary endpoints were sustained remission at 52 weeks, number of relapses, PDN dosage, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) at 26 and 52 weeks, compared to historical cohort.
resultsThe prospective and historical cohorts included 41 and 63 patients, respectively. In the MTX-group, at 26 weeks, 66% of patients were in steroid-free remission and a significant reduction of CRP and ESR was observed, while mean daily PDN dosage dropped to 3.42 mg. Twenty-four subjects reached 52-week phase of the study and 83% maintained GC-free remission. A higher number of relapses were reported in the retrospective cohort (12, 27% vs. 34, 43%), in which up to 49 patients were still taking PDN.
conclusionIn conclusion, upon a subclinical GCA is excluded, MTX at adequate dosages, is a suitable option for the treatment of PMR, allowing a precocious discontinuation of oral GCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.